易瑞沙与特罗凯的比较.PPTVIP

BR.21 and ISEL对照组群的存活曲线显示它们是相似的组群 论文搜集策略摘要 资料搜集策略摘要 个别研究之疾病无恶化期 90% accuracy intervals (any line of therapy) 表皮生长因子受体突变阳性各种治疗疗效 SATURN 研究設計 Stratification factors: EGFR IHC (positive vs negative vs indeterminate) Stage (IIIB vs IV) ECOG PS (0 vs 1) CT regimen (cis/gem vs carbo/doc vs others) Smoking history (current vs former vs never) Region 非鳞状细胞癌 SATURN - OS 全 部 WJTOG0203: 整体存活－依临床特质之亚群分析 0.4 0.6 0.8 1.0 1.2 Favourserlotinib Favoursplacebo HR Male Female Caucasian Asian Adenocarcinoma Squamous-cell Never smoker Former smoker Current smoker HR (95% CI) n 0.88 (0.74–1.05) 659